RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Rsearchers define new step that controls programmed cell death in cancer cells

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.

2 Apr 2011

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

2 Apr 2011

Study: MicroRNA can predict risk of BM in lung cancer patients

Conducting genetic profiles using microRNA can help doctors predict which lung cancer patients are likely to also develop brain metastasis, according to a study published today by Scottsdale Healthcare and the Translational Genomics Research Institute.

1 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of the phase 2b ASPIRE study for TMC435 in treatment experienced hepatitis C patients in a late-breaker session at the 46th Annual meeting of the European Association for the Study of the Liver, Berlin, Germany.

1 Apr 2011

New data confirms antiviral activity of fluvastatin in patients with HCV

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a and ribavirin in a treatment experienced, hepatitis C virus null-responder patient population.

1 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

Asuragen launches new miRNA Biofluids service offering

Asuragen, Inc. announced today the launch of its new miRNA Biofluids service offering designed to interrogate miRNAs from serum, plasma, cerebral spinal fluid, and urine. Supported by a growing body of literature, the utility of miRNA biomarkers in biofluids has been demonstrated for numerous disease areas including Cancer, Neurology, Autoimmune, and Cardiovascular diseases.

31 Mar 2011

Clontech launches new SMARTer Ultra Low RNA Kit

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.

31 Mar 2011

Micro-RNAs appear to play a key role in new mechanism underlying obesity

Max Planck researchers have discovered a new mechanism that leads to the development of type 2 diabetes in obesity. Body weight influences the risk of developing diabetes: between 80 and 90 percent of patients with type 2 diabetes are overweight or obese.

31 Mar 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Pharmasset commences PSI-7977 Phase 2b study against HCV

Pharmasset, Inc. announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C.

30 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

RNA News and Research

Further Reading

Rsearchers define new step that controls programmed cell death in cancer cells

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

Study: MicroRNA can predict risk of BM in lung cancer patients

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

New data confirms antiviral activity of fluvastatin in patients with HCV

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Asuragen launches new miRNA Biofluids service offering

Clontech launches new SMARTer Ultra Low RNA Kit

Micro-RNAs appear to play a key role in new mechanism underlying obesity

RXi Pharmaceuticals to acquire Apthera

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Pharmasset commences PSI-7977 Phase 2b study against HCV

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo